Location History:
- Charlottenlund, DK (2012 - 2014)
- Charlottelund, DK (2017)
Company Filing History:
Years Active: 2012-2017
Title: The Innovative Contributions of Kristian Helin in Cancer Treatment
Introduction
Kristian Helin, an accomplished inventor based in Charlottenlund, Denmark, has made significant strides in the field of cancer research and treatment. With three patents to his name, Helin's work focuses on combating drug resistance in epithelial tumor cells, a critical challenge in oncology. His commitment to innovation is demonstrated through his latest patents, which present novel methods and compounds for enhancing cancer therapy.
Latest Patents
Helin's most recent patents showcase groundbreaking methodologies for treating patients with epithelial cancers. His first invention introduces a method of reducing tumor cell growth and viability by administering a composition that combines a therapeutic amount of an inhibitor of Bruton’s tyrosine kinase (BTK) protein with various chemotherapeutic agents. This synergistic approach could significantly improve the effectiveness of cancer treatments. The second patent focuses on using specific compounds to functionally block genes that contribute to chemotherapy resistance. This invention aims to enhance the therapeutic treatment of epithelial tumor pathologies, offering hope to patients facing drug-resistant cancers.
Career Highlights
Throughout his career, Kristian Helin has collaborated with notable companies such as Bionsil S.r.l. and Bionsil S.r.l. in Liquidazione. His tenure at these organizations has enabled him to develop his patented methodologies further and contribute to the broader scientific community. Helin's research has garnered recognition for its potential to improve patient outcomes and transform cancer treatment paradigms.
Collaborations
In his pursuit of innovative solutions in oncology, Helin has worked alongside esteemed colleagues, including Marialuisa Lavitrano and Emanuela Grassilli. These collaborations have been instrumental in advancing his research and have fostered an environment of knowledge exchange and innovation.
Conclusion
Kristian Helin’s dedication to innovation in cancer treatment underscores the importance of addressing drug resistance in epithelial tumors. His patents represent significant advancements in the field, offering new hope for patients facing challenging cancers. Through his collaborations and professional journey, Helin continues to exemplify the spirit of innovation that drives the quest for effective medical therapies.